Honglin Jiang, Ryan K Muir, R. Gonciarz, A. Olshen, I. Yeh, B. Hann, Ning Zhao, Yung-hua Wang, S. Behr, J. Korkola, M. Evans, E. Collisson, A. Renslo
{"title":"Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors","authors":"Honglin Jiang, Ryan K Muir, R. Gonciarz, A. Olshen, I. Yeh, B. Hann, Ning Zhao, Yung-hua Wang, S. Behr, J. Korkola, M. Evans, E. Collisson, A. Renslo","doi":"10.1084/jem.20210739","DOIUrl":null,"url":null,"abstract":"Jiang et al. report that oncogenic KRAS signaling induces ferrous iron (Fe2+) accumulation throughout mutant KRAS-mediated transformation. Converting an FDA-approved MEK inhibitor into a ferrous iron–activatable drug conjugate (FeADC) achieves potent MAPK blockade in tumor cells with superior systemic tolerability.","PeriodicalId":23015,"journal":{"name":"The Tokushima journal of experimental medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Tokushima journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1084/jem.20210739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12
Abstract
Jiang et al. report that oncogenic KRAS signaling induces ferrous iron (Fe2+) accumulation throughout mutant KRAS-mediated transformation. Converting an FDA-approved MEK inhibitor into a ferrous iron–activatable drug conjugate (FeADC) achieves potent MAPK blockade in tumor cells with superior systemic tolerability.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
